DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
Location: France, Provence-Alpes-Côte d'Azur, Marseille
Employees: 1-10
Total raised: $35.2M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | Aloe Priva... | aloe-group... |
| - | T1D Fund | t1dfund.or... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.05.2023 | Series A | $30.13M | Eli Lilly ... |
| 16.06.2020 | Seed | $5.07M | - |
Mentions in press and media 7
| Date | Title | Description |
| 03.05.2025 | Zucara Therapeutics Secures $25 Million to Combat Diabetes Complications | Zucara Therapeutics is on a mission. The Toronto-based company is tackling a significant challenge in diabetes management: hypoglycemia. Recently, Zucara completed its Series B financing, raising a total of $25 million. This funding is a li... |
| 02.05.2025 | Zucara Therapeutics: $25 Million Series B Closed For Diabetes Life Sciences Platform | Zucara Therapeutics – a diabetes life sciences company developing ZT-01, which is the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes – announced that it has completed the second and f... |
| 20.12.2023 | Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission | We've launched a new Fierce Biotech Fundraising Tracker for 2023 to track all the venture capital flowing into the industry. While biotech VC investments in 2022 failed to live up to 2021's banner year, the second half still saw a steady st... |
| 11.05.2023 | Biotech startup DiogenX secures €27.5M to develop therapeutic solutions for Type 1 diabetes | Marseille-based DiogenX, a preclinical-stage biotech company specialising in the development of pancreatic beta-cell modulators for the treatment of diabetes, announced on Wednesday, May 10, that it has raised €27.5M in a Series A round of ... |
| 10.05.2023 | DiogenX Raises €27.5M in Series A Financing | DiogenX, a Marsille, France-based biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, raised €27.5M in Series A funding. Backers included Roche Venture Fund, Eli Lilly and Company, Omnes, Boeh... |
| 16.06.2020 | DiogenX Raises €4.5M in Seed Financing | DiogenX, a Marseille, France-based preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators for the treatment of type one diabetes (T1D), closed a seed financing round of €4.5m ($4.8M). Backers in... |
| - | DiogenX | “DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options...” |